New drug cocktail aims to stop leukemia return after transplant
NCT ID NCT07686965
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial tests whether a combination of two drugs, lisaftoclax and azacitidine, can help prevent acute myeloid leukemia (AML) from coming back in patients who have already received a stem cell transplant and are at high risk of relapse. Participants are randomly assigned to receive the drug combo or standard observation. The study tracks how long they stay cancer-free and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lisaftoclax plus azacitidine
- What this could lead to
- If successful, this maintenance therapy could reduce the chance of leukemia returning after a stem cell transplant and improve long-term survival for high-risk patients.
- What could go wrong
- This is a Phase 3 trial, but the combination may cause side effects like low blood counts or infections, and it is not yet proven to work better than observation alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New genetic test aims to sharpen blood cancer diagnosis
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- Blood test may personalize leukemia drug dosing
- Engineered immune cells take on tough leukemia in early trial
- New drug combo aims to boost survival in aggressive leukemia